Novo Nordisk fights back as rival offers $49 weight‑loss semaglutide
TL;DR Summary
Novo Nordisk says Hims & Hers’ new $49/month, compounded semaglutide version of Wegovy is illegal mass compounding and unsafe, pledging legal action; the FDA has warned against copycat GLP‑1 drugs. The move intensifies price competition in obesity drugs, with Novo forecasting up to a 13% drop in net sales and shares for Novo Nordisk and Lilly slipping.
- Novo Nordisk hits out at rival Hims & Hers over cheaper weight-loss pill Financial Times
- Novo Nordisk says it will take legal action after Hims & Hers reveals $49 copy of Wegovy pill CNBC
- Cheaper, Generic Weight-Loss Drugs Are Coming Bloomberg
- Hers Expands Personalized Weight Loss Portfolio with Access to Compounded Semaglutide Pills Starting at $49/Month Hims Investor Relations
- Hims launches $49 compounded copy of Wegovy weight-loss pill Yahoo Finance
Reading Insights
Total Reads
0
Unique Readers
13
Time Saved
5 min
vs 5 min read
Condensed
94%
979 → 57 words
Want the full story? Read the original article
Read on Financial Times